Results from the Ariel 5 All-Sky Monitor

1976 ◽  
Vol 350 (1663) ◽  
pp. 505-519 ◽  
Keyword(s):  
First Year ◽  
Temporal Effects ◽  
Transient Source ◽  
Second Year ◽  
Sky Monitor ◽  
Long Term Studies

A summary of results obtained from the first year of Ariel-5 All-Sky Monitor operation is presented. Transient source observations, as well as the results of long-term studies of Sco X-1, Cyg X-3 and Cyg X-1 are described. By example, the included results are indicative of the temporal effects to which the All-Sky Monitor remains sensitive as it begins its second year of observation.

scholarly journals TRUMP’S FOREIGN POLICY: PLANS AND REALITIES

2018 ◽  
pp. 73-82 ◽  
Author(s):  
E. V. Emelianov
Keyword(s):  
Foreign Trade ◽  
The United States ◽  
First Year ◽  
Solar Panels ◽  
White House ◽  
Trade Law ◽  
The Us ◽  
Second Year ◽  
Trade Partners

The article considers the changes in US foreign trade policy at the beginning of the Trump’s presidency. Exporting is a critical component for the long-term growth and the U.S. economy overall, and supporting millions of jobs in US. Though D. Trump campaigned for president as a protectionist, there was no such steps the first year of his presidency. But his second year in the White House began with announcing new tariffs on solar panels, washing machines, then on steel, aluminium. As concerning steel products, the United States being the world’s largest steel importer have persistent trade deficit.The US trade law allows the president to limit imports in case if domestic industries are threatened, against unfair foreign trade practices for a period of time, but such measures were not frequent in US practice. Meanwhile new protectionist measures are debated. Trump’s policy is being opposed not only by trade partners of the US, but in the US as well, by those who argue that protectionist measures will complicate international relationships.

A Decade of Mark-Recapture of Platypuses on The Duckmaloi River: Any New Insights into Population Dynamics?

1998 ◽  
Vol 20 (2) ◽  
pp. 302
Author(s):  
D. Goldney
Keyword(s):  
Sex Ratio ◽  
New South ◽  
First Year ◽  
Mark Recapture ◽  
South Wales ◽  
Adult Status ◽  
Second Year ◽  
Gill Netting ◽  
Population Numbers

A long-term mark-recapture program has been carried out on the Duckmaloi Weir (near Oberon, New south Wales) and associated river over the period 1986 to the present. The pipehead weir creates a long shallow ·pool' about 2.5 ha in area, ideal for gill-netting platypuses. One hundred and eighty-two (182) individual animals have been captured in excess of 500 times. The majority of animals have been captured in the weir pool. A very dynamic situation exists with new adults and juveniles being captured on a regular basis and conversely captured animals "disappearing" on a regular basis from the system. Some individuals exhibit both transience and site attachment characteristics. However, relatively few animals remain site attached for long periods of time. Sixty nine percent of individuals are captured two or fewer times. Band loss cannot account for this phenomenon. Of the captured animals, 11.3% have been caught more than 5 times. The sex ratio of the population favours females in first capture adults (1:1.72) but males in first capture juveniles (1:0.73). Females are more likely to be recaptured than males. The sex ratio of juveniles varies significantly from year to year. The period between recaptures varies greatly and can be up to 6 years. Four animals have been captured over nine years (3 females/1 male) but no animal has been captured every year of the study. Recruitment has occurred at levels able to maintain the current population numbers. Thirty percent of available adults have been found lactating, including second year females. Seventy one percent of first year capture juveniles and 89.9% of first capture adults "disappear" within two years of first capture. Forty two percent of juvenile animals reach adult status before "disappearing".

scholarly journals Use of Sickness Benefits by Patients With Metastatic Breast Cancer – A Swedish Cohort Study

2021 ◽  
Author(s):  
Renske Altena ◽  
Sofie A.M. Gernaat ◽  
Ulla Wilking ◽  
Narsis A. Kiani ◽  
Aina Johnsson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Well Being ◽  
First Year ◽  
Study Population ◽  
Sickness Benefits ◽  
Second Year ◽  
New Diagnosis

Abstract Background Advances in the treatment of metastatic breast cancer (mBC) have led to improved life expectancy. Many cancer survivors desire to return to paid work to enhance their sense of well-being. For patients with mBC, little is known about how the diagnosis impacts ability to work or the factors that increase the need for sickness benefits. Patients and methods Data were collected from two Swedish national registers, for females ages 18 to 63 years in the Stockholm-Gotland healthcare region with a new diagnosis of mBC from 1997 through 2011. Type of first-line palliative treatment was identified in medical records of a subset of the study population. Use of sickness absence (SA) and disability pension (DP) by these patients during the year before and one and two years after mBC diagnosis was determined from a third register. Regression analysis was performed to ascertain which covariate factors were associated with long-term (> 30 days) SA. Results A total of 1,240 patients were evaluated the year before and the first year after mBC diagnosis; only 805 patients were still alive and evaluated the second year after diagnosis. The proportions of patients having SA and DP were 56.0% and 24.8% the year before, 69.9% and 28.9% the first year after, and 64.0% and 34.7% the second year after diagnosis, respectively. Adjusted odds of having long-term SA were significantly higher at 1 and 2 years after diagnosis for patients with age < 45 years (AOR = 3.43 and AOR = 1.70, respectively), early calendar year of diagnosis (AOR = 1.72 and AOR = 1.79, respectively), metachronous mBC (AOR = 4.85 and AOR = 4.52, respectively), and SA ≥ 90 days the year before diagnosis (AOR = 3.44 and AOR = 1.98, respectively). Odds were also significantly higher the second after diagnosis for patients treated with chemotherapy (AOR = 1.81) or radiotherapy (AOR = 2.23), compared to those treated with hormonal therapy, Conclusions Rates of SA and DP increase after a diagnosis of mBC. Women who are younger, develop metachronous mBC, use SA heavily before mBC, and receive chemotherapy or radiotherapy have a greater need for sickness benefits after an mBC diagnosis.

scholarly journals Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2527-2527 ◽  
Author(s):  
Faizan Khan ◽  
Alvi Rahman ◽  
Marc Carrier ◽  
Clive Kearon ◽  
Jeffrey I. Weitz ◽  
...  
Keyword(s):  
Board Of Directors ◽  
Anticoagulant Therapy ◽  
Research Funding ◽  
Meta Analysis ◽  
First Year ◽  
Advisory Committees ◽  
Men And Women ◽  
Second Year ◽  
Recurrent Vte

Abstract Background: The optimal duration of anticoagulation after a first unprovoked venous thromboembolism (VTE) is uncertain. Anticoagulant therapy is highly effective at reducing the risk of recurrent VTE, but this clinical benefit is not maintained once anticoagulation is stopped. Current guidelines suggest considering indefinite anticoagulation in all patients with unprovoked who have a non-high bleeding risk. However, this is a weak recommendation based on limited evidence. Deciding whether patients with a first unprovoked VTE should be considered for indefinite anticoagulant therapy requires estimation of the long-term risk of recurrent VTE after stopping anticoagulation. This risk however, is poorly established, hindering decision making. Methods: We performed a systematic review and meta-analysis of randomized clinical trials and prospective observational studies to determine the rate of recurrent VTE in the first year, in the second year, between years 2 and 5, and years 5 and 10; and the cumulative incidence for recurrent VTE at 2, 5 and 10 years after stopping anticoagulation in men and women with first unprovoked VTE, who had completed at least 3 months of initial treatment. Studies were identified through a comprehensive literature search using MEDLINE, EMBASE and the Cochrane CENTRAL databases. Data clarifications were requested from authors of eligible studies. Rates of recurrent VTE were calculated for each study from the total number of recurrent VTE events divided by the person-years of follow-up, and then pooled using random-effects meta-analysis. Results: Fourteen studies involving 6, 446 patients were included in the analysis. Among men with a first unprovoked VTE, the pooled rate of recurrent VTE per 100 person-years after stopping anticoagulation was 11.2 events (95% CI, 9.0-13.6) in the first year; 7.4 events (95% CI, 5.5-9.5) in the second year; 4.4 events/year (95% CI, 3.2-5.7) between years 2 and 5, and 3.8 events/year (95% CI, 1.6-6.9) between years 5 and 10 [Table 1]. Among women with a first unprovoked VTE, the pooled rate of recurrent VTE per 100 person-years after stopping anticoagulation was 8.6 events (95% CI, 6.5-11.0) within the first year; 5.2 events (95% CI, 3.5-7.2) in the second year; 3.0 events/year (95% CI, 1.6-4.7) between years 2 and 5, and 2.0 events/year (95% CI, 1.3-2.9) between years 5 and 10 [Table 1]. In men and women respectively, the cumulative incidence for recurrent VTE was 17.8% (95% CI, 14.0%-21.9%) and 13.4% (95% CI, 9.8%-17.4%) at 2 years, 28.2% (95% CI, 22.0%-34.4%) and 20.9% (95% CI, 14.0%-28.5%) at 5 years, and 40.8% (95% CI, 28.0%-53.9%) and 28.5% (95% CI, 19.5%-38.3%) at 10 years after stopping anticoagulant therapy [Table 2]. Conclusions: Among patients with a first unprovoked VTE who have completed at least 3 months of initial treatment, men have a higher long-term risk of recurrent VTE after stopping anticoagulation, and may be given greater consideration for indefinite anticoagulant therapy. Our findings affirm the importance of considering patient's sex in deciding the optimal duration of anticoagulation, and as such, emphasize the need for individualized, patient-centered approach for the long-term management of unprovoked VTE. Disclosures Carrier: BMS: Honoraria, Research Funding; Leo Pharma: Research Funding; Pfizer: Honoraria; Bayer: Honoraria. Weitz:Bristol-Myers Squibb: Honoraria; Daiichi-Sankyo: Honoraria; Ionis: Consultancy, Honoraria; Janssen: Honoraria; Servier: Honoraria; Novartis: Honoraria; Bayer: Honoraria; Boehringer Ingelheim: Honoraria, Research Funding. Schulman:Boehringer-Ingelheim: Honoraria, Research Funding; Daiichi-Sankyo: Honoraria; Sanofi: Honoraria; Bayer: Honoraria. Couturaud:Pfizer: Research Funding; Bayer: Honoraria, Other: Travel Support; AstraZeneca: Honoraria; Actelion: Other: Travel Support; Intermune: Other: Travel Support; Leo Pharma: Other: Travel Support; Daiichi Sankyo: Other: Travel Support. Becattini:Bayer HealthCare: Other: Lecture Fees; Boehringer Ingelheim: Other: Lecture Fees; Bristol Meyer Squibb: Other: Lecture Fees. Agnelli:Daiichi Sankyo: Other: Personal Fees; Boehringer Ingelheim: Other: Personal Fees; Bayer Healthcare: Other: Personal Fees; Pfizer: Other: Personal Fees; Bristol-Myers-Squibb: Other: Personal Fees. Brighton:Glaxo Smith Klein: Other: Personal Fees; Novo Nordisk: Other: Personal Fees; Bayer: Other: Personal Fees. Lensing:Bayer: Employment. Prins:Pfizer: Consultancy; Daiichi Sankyo: Consultancy. Hutton:Cornerstone Research Group: Honoraria. Palareti:Roche: Membership on an entity's Board of Directors or advisory committees; Werfen: Speakers Bureau; Alfa-Wassermann: Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees. Prandoni:Pfizer: Consultancy; Daiichi-Sankyo: Consultancy; Sanofi: Consultancy; Bayer: Consultancy. Büller:Pfizer: Consultancy, Research Funding; Daiichi-Sankyo: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Sanofi-Aventis: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Bayer: Consultancy, Research Funding; Boehringer Ingelheim: Consultancy, Research Funding; Thrombogenics: Consultancy, Research Funding; Isis: Consultancy, Research Funding; GlaxoSmithKline: Consultancy, Research Funding. Rodger:Biomerieux: Research Funding.

Response of birds to a wildfire in the Great Western Woodlands, Western Australia.

2013 ◽  
Vol 19 (4) ◽  
pp. 188 ◽  
Author(s):  
Harry F Recher ◽  
William E Davis Jr
Keyword(s):  
Western Australia ◽  
Fire Frequency ◽  
First Year ◽  
Large Area ◽  
Burnt Area ◽  
Open Country ◽  
Second Year ◽  
Eucalypt Woodland ◽  
Number Of Individuals

In December 2005, a wildfire burnt a large area of semi-arid eucalypt woodland along ~10 km of the Norseman- Coolgardie Road north of Norseman in the Great Western Woodlands (GWW), Western Australia. Few birds used the burnt area in the first year after the fire and these were mainly ground and shrub foraging insectivores. There was no influx of seed-eaters or open-country species as reported for post-fire habitats elsewhere in southern Australia. The greatest number of individuals and species of birds occurred in the second year post-fire when ground and shrub vegetation was floristically most diverse. Canopy foragers were attracted to the burnt area in the second year by an outbreak of psyllid insects on seedling eucalypts. At the same time, bark dwelling arthropods associated with the standing stems of fire-killed eucalypts attracted bark-foragers. From the third year, small insectivorous ground, shrub, and canopy foragers dominated the avifauna on the burnt area. These foraged on fire-killed shrubs, as well as living vegetation, including the lignotuberous regrowth of eucalypts. Bark foragers were uncommon after the second year. Throughout the study, the burnt area had fewer species and individuals than adjacent unburnt habitats. Compared with unburnt woodlands there were few differences in how species foraged on the burnt plots, but most species foraged lower reflecting the stature of the vegetation in the burnt woodland. Nectar-feeders, fruit-eaters, large insectivores, raptors, and parrots, although common in the unburnt woodland, were absent or rare in the burnt area. This reflected the limited regrowth of vegetation on the burnt area, which lacked the structural and floristic complexity of nearby unburnt woodlands. Ground foragers probably commenced nesting on the burnt area in the first year, with shrub and canopy foragers nesting from the second year. However, after five years, there was no evidence of large insectivores, nectar-feeders, raptors, seed-eaters, or foliage-eaters (i.e., parrots) nesting despite their abundance in adjacent unburnt woodland. Some of the unburnt woodlands monitored in this study were even-aged regeneration estimated to be 30–50 years post-fire or logging. Regardless of origin, these even-aged plots lacked the diverse avifauna associated with mature woodlands and suggest that post-fire recovery of birds and vegetation in these woodlands is likely to take decades and probably more than 100 years. If so, human activities that increase fire frequency in the GWW, including climate change and fuel-reduction burns, will have long-term adverse impacts on regional biodiversity exceeding those associated with wildfires in less arid forests and woodlands where rates of recovery are more rapid.

scholarly journals Making Sure PaLRaP Remains Healthy and Strong

2014 ◽  
Vol 2 (1) ◽  
pp. 1-5
Author(s):  
John Barnett ◽  
Tom Reinsfelder
Keyword(s):  
Early Growth ◽  
Editorial Team ◽  
First Year ◽  
Second Year ◽  
The Many

Thanks to the many contributions of numerous individuals, Pennsylvania Libraries: Research & Practice (PaLRaP) has been quite successful and well-received in its first year of existence. As we head into the second year of publication, members of the editorial team must now shift our focus from the initial stages of creation and early growth to the next phase of ongoing improvement and sustainability over the long term.

Modified Rankin scale as a determinant of direct medical costs after stroke

2017 ◽  
Vol 12 (4) ◽  
pp. 392-400 ◽  
Author(s):  
Sarah Dewilde ◽  
Lieven Annemans ◽  
Andre Peeters ◽  
Dimitri Hemelsoet ◽  
Yves Vandermeeren ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Resource Use ◽  
Medical Costs ◽  
First Year ◽  
Modified Rankin Scale ◽  
Scale Level ◽  
Degree Of Disability ◽  
Second Year ◽  
Total Average

Background Resource use in the acute and subacute phases after stroke depends on the degree of disability. Aims To determine if direct costs after stroke also vary by level of disability as measured using the modified Rankin scale at the chronic stage after stroke. Methods In a multicentre study, we collected acute and chronic in- and outpatient resource use in survivors of ischemic stroke stratified by levels of disability according to the modified Rankin Scale. Statistical inference on costs at each level of the modified Rankin Scale was estimated using a general linear model for the first three months, the first year, and any subsequent year after ischemic stroke. Results A total of 569 survivors of ischemic stroke with a mean age of 71.7 years were enrolled (41% female) from 10 academic and nonacademic centers. Costs varied substantially over time and with each modified Rankin Scale level. The total average costs in the first year were estimated $33,147 per patient, ranging from $9,114 for modified Rankin Scale 0 to $83,236 for modified Rankin Scale 5. In the second year, medical costs were on average $14,039, varying from $2,921 to $39,723 for patients with modified Rankin Scale 0–5. The level of disability based on the modified Rankin Scale was a major determinant of resource use, irrespective of age, gender, atrial fibrillation, and vascular risk factors. Conclusion Long-term resource use after stroke is high and is mainly driven by degree of disability as measured by the modified Rankin scale.

scholarly journals Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2059-2059 ◽  
Author(s):  
Wolfgang Miesbach ◽  
Karina Meijer ◽  
Michiel Coppens ◽  
Peter Kampmann ◽  
Dr. Klamroth ◽  
...  
Keyword(s):  
Board Of Directors ◽  
Research Funding ◽  
Factor Ix ◽  
First Year ◽  
Severe Hemophilia ◽  
Advisory Committees ◽  
The Mean ◽  
Second Year

Background: The aim of gene therapy is to provide long-term therapeutic effect from a single administration, yet information on response durability is currently limited. AMT-060 is an adeno-associated virus serotype 5 (AAV5) vector with a codon-optimized wildtype human factor IX (FIX) gene and liver-specific promoter. AMT-060 is being analyzed in an ongoing study of 10 participants with severe/moderate-severe hemophilia B (Phase 1/2 study, NCT02396342). Aim: To describe efficacy and safety outcomes from a planned interim analysis at up to 4-years post-AMT-060. Methods: Adult males with FIX activity ≤2% and a severe bleeding phenotype received a single intravenous infusion of AMT-060 (5x1012gc/kg, Cohort 1, n=5) or (2×1013 gc/kg, Cohort 2, n=5). Assessments included FIX activity, FIX replacement use, annualized bleeding rate (ABR), treatment-related adverse events (TRAE), immunological and inflammatory biomarkers up to 4 years (Cohort 1) and 3.5 years (Cohort 2). Results: As of 8 May 2019, for Cohort 1 the mean yearly FIX activity (annualized to 4 years) was 6.0 as compared to 4.4% in the first year, 6.8% in the second year and 7.3% in the third year. Mean yearly FIX activity for Cohort 2 at 3 years was 7.9% as compared to 7.1% in the first year and 8.4% in the second year. Factor IX activity for each patient over the length of follow up is shown in Figure 1. Eight of 9 participants using prophylaxis at baseline were able to discontinue use. During the last 12 months of observation, the mean annualized bleed rate (ABR) was 1.7 for Cohort 1 and 0.7 for Cohort 2. Respectively, these represent a reduction in mean ABR to the year prior to treatment of 88% and 83%. During this same period the consumption of FIX replacement therapy declined 93% and 96% relative to pre-treatment respectively for Cohort 1 and Cohort 2. No participants developed FIX inhibitors or signs of sustained AAV5 capsid-specific T-cell activation. TRAE were mainly reported in the first 3.5-months after treatment, including three participants who experienced transient mild elevations in alanine aminotransferase as previously described. One new TRAE (joint swelling post-exercise) was observed during the last 12 months of observation post-treatment. Updated data, up to 4-years of observation, will be presented for the first time. Conclusions: Long-term stable endogenous FIX activity and reductions in ABR and FIX replacement use were observed following a single treatment with AMT-060. There were no additional safety concerns with longer term follow-up. These findings support the ongoing Phase III study of the enhanced construct, AMT-061, which encodes the highly active Padua FIX variant. Figure 1 Disclosures Miesbach: Bayer, BioMarin, CSL Behring, Chugai, Freeline, Novo Nordisk, Octapharma, Pfizer, Roche, Takeda/Shire, UniQure: Consultancy; Bayer, Novo Nordisk, Octapharma, Pfizer, Takeda/Shire: Research Funding; Bayer, Chugai, Novo Nordisk, Octapharma, Pfizer, Takeda/Shire, UniQure: Speakers Bureau. Meijer:Pfizer, Sanquin, Uniqure: Research Funding; Uniqure, BMS, Aspen, Boehringer Ingelheim, Sanquin, Bayer: Consultancy, Honoraria; Sanquin: Research Funding; Bayer: Research Funding. Coppens:Pfizer: Honoraria; Portola Pharmaceuticals, Inc: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; Uniqure: Research Funding; Boehringer Ingelheim: Research Funding; Sanquin Blood Supply: Research Funding; Bayer: Honoraria, Research Funding; CSL Behring: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria. Kampmann:Uniqure BV: Research Funding. Klamroth:Bayer, Biomarin, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, SOBI, Takeda: Consultancy; Bayer, Novo Nordisk, SOBI: Research Funding. Schutgens:Baxalta Shire, Novo Nordisk, Bayer, CSL Behring, Pfizer, UniQure BV: Research Funding. Castaman:Bayer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sobi: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; CSL Behring: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda (SHIRE): Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kedrion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Werfen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Research Funding; Uniqure: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Seifried:Medac: Other: BSD owns IP and is contract manufacturer; Uniqure BV: Research Funding. Schwaeble:Uniqure BV: Research Funding. Bönig:Celgene, Novartis, Sandoz Hexal: Consultancy; Kiadis Pharma: Other: Contract manufacturing of ATIR101; Sandoz Hexal, Uniqure: Research Funding; Miletenyi: Speakers Bureau. Sawyer:Uniqure BV: Employment. Leebeek:CSL Behring: Research Funding; UniQure: Consultancy; Shire/Takeda: Research Funding; Novo Nordisk: Consultancy; Sobi: Other: Travel grant; Shire/Takeda: Consultancy.

scholarly journals SAT-LB15 24-Month Efficacy and Safety of Once Weekly and Every Other Week Administration of GX-H9, Hybrid FC-Fused Long-Acting Human Growth Hormone: A Phase 2 Study in Children With Growth Hormone Deficiency

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Oleg Malievskiy ◽  
Aryaev Mykola ◽  
Nataliya Zelinska ◽  
Elena Bolshova ◽  
Ganna Senatorova ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Treatment Period ◽  
Study Drug ◽  
Hormone Deficiency ◽  
Height Velocity ◽  
First Year ◽  
Efficacy And Safety ◽  
Second Year ◽  
Long Acting

Abstract Objectives GX-H9 is a long-acting form of recombinant human GH under clinical development for both adults and children with GHD. In this report, 24-month efficacy and safety of once weekly and every other week (EOW) administration of GX-H9 were evaluated, in addition to Genotropin® switch-ability to GX-H9 after 12-month of treatment. Methods Subjects were randomly assigned to receive either one of three doses of GX-H9 (0.8 mg/kg/week, 1.2 mg/kg/week or 2.4 mg/kg every other week) or 0.03 mg/kg/day of Genotropin®. Treatment duration is 24-month for all patients in GX-H9 arms while patients in Genotropin® arm were re-randomized to one of three doses of GX-H9 at the completion of the first 12-month of treatment. Doses of GX-H9 were adjusted throughout the treatment period whenever necessary, based on IGF-1 levels. Results Out of 56 randomized, 54 received either GX-H9 or Genotropin®. Fifty subjects completed the 12-month treatment period. Of 50, 45 subjects completed the next 12-month, comprising 33 patients from GX-H9 and 12 patients who switched from Genotropin®. First year/second year mean±SD annualized height velocity (aHV) for 0.8 mg/kg/week, 1.2 mg/kg/week or 2.4 mg/kg every other week of GX-H9 were 10.50±2.54/9.14±1.96, 11.76±1.96/9.88±1.92 and 11.03±2.92/9.72±1.90 cm/year, respectively. First year mean±SD aHV for Genotropin® was 9.14±3.09 cm/year. Patients switched to one of the three doses of GX-H9 in the second year showed comparable aHV in the second year (8.73±2.69/7.60±0.90/9.13±1.07 cm/year for 0.8 mg/kg/week, 1.2 mg/kg/week and 2.4 mg/kg/EOW GX-H9, respectively). No significant slow-down of the growth was observed in the second year from patients who received GX-H9 throughout and patients who switched from Genotropin®. Mean change in height SDS after 12 months/24 months of GX-H9 treatment throughout from baseline treatment improved continuously (+1.10/+1.61 and +1.31/+1.89 and +1.15/+1.69 for 0.8 mg/kg/week, 1.2 mg/kg/week and 2.4 mg/kg EOW GX-H9, respectively). First year mean change in height SDS for Genotropin® was +0.92 SDS, and showed comparable improvement in height SDS after switching to GX-H9 weekly arms (+0.76 and +0.79 SDS for 0.8 mg/kg/week and 1.2 mg/kg/week, respectively). Most treatment-emergent adverse events were evaluated as unrelated to the study drug and were mild or moderate in severity. No new safety concerns were observed throughout 24 months of long-term GX-H9 treatment or after switching to GX-H9 from Genotropin®.Conclusions Growth response and safety profile of GX-H9 in children with GHD is comparable to those of daily GH, achieving robust growth rates after 24-month treatment. Subjects switched from Genotropin® in the second year, also showed substantial catch-up growth indicated by improvement in height SDS. GX-H9 has a unique potential to be a convenient long-term GH providing not only weekly but also twice-monthly treatment.

scholarly journals Five-year experience in providing medical care to patients with bronchopulmonary pathology with chronic hypoxemic respiratory failure

2020 ◽  
Vol 64 (3) ◽  
pp. 117-123
Author(s):  
Olga N. Titova ◽  
Natalia A. Kuzubova ◽  
Vladimir A. Volchkov ◽  
Andrey G. Kozyrev ◽  
Darya B. Skljarova
Keyword(s):  
Respiratory Failure ◽  
Medical Care ◽  
First Year ◽  
Hypoxemic Respiratory Failure ◽  
Copd Patients ◽  
Oxygen Concentrator ◽  
Second Year ◽  
To Receive ◽  
Long Term Oxygen Therapy

Introduction. The article considers the management of medical care for patients with chronic hypoxemic respiratory failure (CHRF), including long-term oxygen therapy (LOT). To achieve this goal in 2013 there was established the St. Petersburg Municipal Pulmonary Center (MPC). The study aimed to assess the results of the MPC activity in 2014 - 2LC138727590CN018. Material and methods. The medical records of patients admitted to the MPC in 2014-2018 were studied. To process the information conventional statistical methods were used. Results. Over the past 5 years, MRC specialists have consulted 13,239 patients, mainly COPD cases. 1,054 patients with CHRF were hospitalized for an additional examination, and 435 cases were indicated to receive LOT. The necessary oxygen concentrator facilities were provided at the expense of the St. Petersburg city budget. Mortality rate accounted for 10.4% by the end of the first year of LOT, 15.1% by the end of the second year, reaching 27.0% and 38.3% by the end of the third and fourth years, respectively. In the group of COPD patients with CHRF (262 patients, 238 men, and 24 women, at the average age of 69 ± 3 years), LOT was accompanied by a decrease in the number of severe exacerbations of the disease (before the LOT - 3 (3; 4) severe exacerbations per year, after a year - 2 (1; 2); p <0.001), as well as cases of referral and duration of stay in the intensive care unit. This led to a decrease in the average cost of inpatient treatment from 264,912 ± 31,277 rubles per year to 134,826 ± 21,277; p <0.001. Conclusion. Early verification and correction of CHRF contribute not only to the decline in the number of exacerbations of respiratory disease but also to the reduction of financial costs necessary for the treatment of such patients.

Sign in / Sign up

Export Citation Format

Share Document